Good practices in Rituximab Administration: Integrative Literature Review
DOI:
https://doi.org/10.32635/2176-9745.RBC.2022v68n3.2194Keywords:
rituximab/administration & dosage, antineoplastic combined chemotherapy protocols, antineoplastic protocolsAbstract
Introduction: Rituximab is a mouse/human chimeric monoclonal antibody, widely used in the therapeutic setting of various diagnoses, due to its different administration, management and adverse effects protocols; its use requires attention by the healthcare team. Objective: Describe the infusion protocols for rituximab in the first, subsequent and desensitization infusions, and characterize their safety. Method: Integrative literature review. The search was performed in databases and electronic libraries: LILACS, PubMed, MEDLINE, SciELO and BDEnf. Results: In all, 413 articles were eligible after crossing the descriptors. Of these, 113 were read in full and eventually, 16 articles matched the study design. The articles were published from 2016 to 2020, predominantly in English (87.5%). Concerning the main routes of administration in the studies included, nine addressed the intravenous infusion (in different modalities of time) and seven, subcutaneously. Conclusion: According to the scientific literature, all intravenous and subcutaneous infusion modalities are shown to be safe and effective if the protocols are correctly selected and applied.
Downloads
References
Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017;8(1):12. doi: https://doi.org/10.1007/s13317-017-0100-y
Santos JE, Fiel D, Santos R, et al. Uso do rituximabe em glomerulopatias em adultos e justificativas. J Bras Nefrol. 2020;42(1):77-93. doi: https://doi.org/10.1590/2175-8239-JBN-2018-0254
Laudati C, Clark C, Knezevic A, et al. Hypersensitivity reactions: priming practice change to reduce incidence in first-dose rituximab treatment. Clin J Oncol Nurs. 2018;22(4):407-14. doi: https://doi.org/10.1188/18.CJON.407-414
Bupathi M, Hajjar J, Bean S, et al. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Invest New Drugs. 2017;35(1):59-67. doi: https://doi.org/10.1007/s10637-016-0395-y
Ganong LH. Integrative reviews of nursing research. Res Nurs Health. 1987;10(1):1-11. doi: https://doi.org/10.1002/nur.4770100103
Araújo WCO. Recuperação da informação em saúde: construção, modelos e estratégias. ConCI. 2020;3(2):100-34. doi: https://doi.org/10.33467/conci.v3i2.13447
Joanna Briggs Institute. JBI levels of evidence [Internet]. Australia: Joanna Briggs Institute; 2013 Oct [cited 2018 Nov 1]. Available from: https://jbi.global/sites/default/files/2019-05/JBI-Levels-of-evidence_2014_0.pdf
Levin AS, Otani IM, Lax T, et al. Reactions to rituximab in an outpatient infusion center: a 5-year review. J Allergy Clin Immunol Pract. 2017;5(1):107-13. doi: https://doi.org/10.1016/j.jaip.2016.06.022
Hartinger JM, Satrapová V, Hrušková Z, et al. Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience. Eur J Hosp Pharm. 2019;26(4):210-13. Disponível em: http://doi.org/10.1136/ejhpharm-2017-001454
Fenton TT, Crawford BS, Bullington SM. Implementation and evaluation of a 90-minute rituximab infusion protocol at the Richard L. Roudebush VA Medical Center. Fed Pract. 2020;37(7):331-5. Cited in: PubMed; PMID 32908338.
Dotson E, Crawford B, Phillips G, et al. Sixty-minute infusion rituximab protocol allows for safe and efficient workflow. Support Care Cancer. 2016;24(3):1125-9. doi: https://doi.org/10.1007/s00520-015-2869-4
Cho KM, Keam B, Ha H, et al. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. Korean J Intern Med. 2019;34(4):885-93. doi: https://doi.org/10.3904/kjim.2017.036
Bruneto RV, Arruda GN, Fernandes KT, et al. Anticorpos monoclonais no tratamento oncológico: revisão de literatura para o atendimento ao paciente e manejo das reações infusionais. Arch Health Sci [Internet]. 2019 [acesso 2020 mar 23];26(3):173-8. Disponível em: https://repositorio-racs.famerp.br/racs_ol/vol-26-3/anticorpos-monoclonais-no-tratamento-oncologico-revisao-de-literatura-para-o-atendimento-ao-paciente-e-manejo-das-reacoes-infusionais.pdf
Yang BC, Castells MC. Rituximab hypersensitivity and desensitization: a personalized approach to treat cancer and connective tissue diseases. Ann Allergy Asthma Immunol. 2019;123(1):11-5. doi: https://doi.org/10.1016/j.anai.2019.03.008
Wong JT, Long A. Rituximab hypersensitivity: evaluation, desensitization, and potential mechanisms. J Allergy Clin Immunol Pract. 2017;5(6):1564-71. doi: https://doi.org/10.1016/j.jaip.2017.08.004
Novelli S, Soto L, Caballero A, et al. Assessment of confirmed clinical hypersensitivity to rituximab in patients affected with B-Cell neoplasia. Adv Hematol. 2020;2020:4231561. doi: https://doi.org/10.1155/2020/4231561
Stewart D, Aucoin JS, Crosbie T, et al. Update on the subcutaneous administration of rituximab in Canadian Cancer Centres. Curr Oncol. 2020;27(2):113-6. doi: https://doi.org/10.3747/co.27.6041
Kashiura D, Souza PVS, Santos HT, et. al. Modelo de impacto orçamentário do rituximabe subcutâneo comparado ao intravenoso no tratamento do linfoma não Hodgkin difuso de grandes células B, CD-20 positivo, no sistema de saúde suplementar brasileiro. J Bras Econ Saúde. 2018;10(3):255-61. doi: https://doi.org/10.21115/JBES.v10.n3.p255-61
Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102(11):1913-22. doi: https://doi.org/10.3324/haematol.2017.173583
Davies A, Berge C, Boehnke A, et al. Subcutaneous rituximab for the treatment of B-Cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017;34(10):2210-31. doi: https://doi.org/10.1007/s12325-017-0610-z
MacDonald D, Crosbie T, Christofides A, et al. A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma. Curr Oncol. 2017;24(1):33-9. doi: https://doi.org/10.3747/co.24.3470
Rummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017;28(4):836-42. doi: https://doi.org/10.1093/annonc/mdw685
De Cock E, Kritikou P, Sandoval M, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One. 2016;11(6):e0157957. doi: https://doi.org/10.1371/journal.pone.0157957
MabThera® (rituximabe) [bula na Internet]. Rio de Janeiro: Roche; 2018 [acesso 2021 mar 6]. Disponível em: https://dialogoroche.com.br/content/dam/roche-dialogo/dialogo-brazil-assets/downloadable-assets/produtos/bulas/mabthera/Mabthera_Bula_Profissionais_da_Saude.pdf
Department of Health and Human Services (US), National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 [Internet]. Bethesda, (MD): Cancer Therapy Evaluation Program; 2009 May 28 [revised 2010 June 14; cited 2021 Mar 6]. Available from: https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf
Silva DP, Guimarães Filho JS, Brandemberg JC. A praxeologia da regra de três algebrizada e a proposição cinco do Liber Quadratorum. RECM. 2020;16(35):61-73. doi: http://doi.org/10.18542/amazrecm.v16i35.8270
Published
How to Cite
Issue
Section
License
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
This work is licensed under a Creative Commons Attribution 4.0 International License.
